A novel more effective genotoxic therapy for ovarian cancer
一种新的更有效的卵巢癌基因毒性疗法
基本信息
- 批准号:10440098
- 负责人:
- 金额:$ 39.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:ATR geneAddressBehaviorBioinformaticsCCNE1 geneCRISPR/Cas technologyCancer PatientCandidate Disease GeneCell Cycle CheckpointCessation of lifeCharacteristicsChemoresistanceClinicClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCombined Modality TherapyDNA Double Strand BreakDNA replication forkDNA sequencingDataDefectDependenceDouble Strand Break RepairDrug resistanceFrequenciesFutureGenesGeneticGenome StabilityGenomicsHumanIn VitroLeadMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryModelingMonitorMusMutationPatientsPhosphotransferasesPlatinumPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) PolymerasesPositioning AttributePrimary NeoplasmProteinsProteomicsRecurrenceRelapseReportingResistanceRoleSamplingSerousTP53 geneTestingTherapeuticTumor PromotionTumor SuppressionValidationbiomarker identificationbrca genecancer cellcancer geneticscancer therapycombinatorialeffectiveness testingefficacy evaluationefficacy testingexperimental studygenotoxicityhomologous recombinationimprovedinhibitorinnovationinsightknock-downnovelnovel therapeuticsoverexpressionpatient derived xenograft modelpatient populationpatient stratificationpre-clinicalpreclinical trialpredictive markerpreventrelapse preventionresistance mechanismresponseresponse biomarkersynergismtargeted treatmenttranscriptometranscriptome sequencingtransgene expressiontreatment optimizationtreatment strategytumor
项目摘要
PROJECT SUMMARY
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy. More than 80% of
HGSOC patients recur after frontline standard therapy, and complete and durable responses are rare. Therapies
that improve compete tumor regression and prevent relapse are needed. Our GOALS are to i) identify which
ovarian cancer genetic subsets will benefit from a new more effective genetically targeted therapy using primary
tumor cultures, patient-derived xenograft models and human tumor samples from our clinical trial, ii) identify
mechanisms of acquired resistance with genetic validation.
We have identified a novel and highly active genotoxic therapy by co-inhibiting poly-ADP ribose polymerase
(PARP) and ATR checkpoint kinase. Combination PARP inhibition with ATR inhibition (PARPi-ATRi) synergizes
to specifically target and kill HGSOCs harboring common HGSOC-associated alterations, e.g. homologous
recombination (HR) deficiency and Cyclin E overexpression. Our preliminary studies show that PARPi-ATRi in
combination is especially effective in killing HGSOC cells with these alterations and causes regression of HR-
deficient and Cyclin E overexpressing HGSOC patient-derived xenografts (PDXs). These results have stimulated
a clinical trial of PARPi-ATRi combination in recurrent HGSOC (unselected patient population) to be led by the
PI of this proposal. This will be the first trial evaluating PAPRi-ATRi combination in ovarian cancer.
Here, we propose to validate in vitro findings and expand the use of our PDX model, a reliable HGSOC
surrogate, to test the effectiveness of this novel PARPi-ATRi combination in killing HGSOCs that either
overexpress Cyclin E-or have acquired PARPi-resistance, which together cause most deaths from HGSOC. Our
clinical trial of PARPi-ATRi for treatment of recurrent HGSOC will be performed in parallel with the expanded
preclinical mouse studies. This will allow us to correlate predictive biomarkers (HR-deficiency and Cyclin E
overexpression) of response and potential resistance mechanisms (e.g., BRCA reversion mutations).
This PARPi-ATRi combination therapy is promising; however, this treatment causes tumor regression initially
in chemo-resistant Cyclin E-overexpressing tumors but acquired resistance ultimately develops. Using genomic
and proteomics, we will integrate alterations discovered in the PAPRi-ATRi-resistant and sensitive PDXs with
patient samples from the clinical trial to develop a candidate pool list. Candidate genes associated with resistance
will be refined by prioritizing alterations found at both the gene and protein level and that are druggable. The top
candidates will be validated in vitro using a targeted CRISPR knock-down approach. Defining markers of
response and resistance will help stratify patient populations, optimize treatment strategies and identify new
targets for future therapeutics based on HGSOC cancer genetics.
项目摘要
高级别浆液性卵巢癌(HGSOC)是最致命的妇科恶性肿瘤。80%以上
HGSOC患者在一线标准治疗后复发,完全和持久的反应是罕见的。疗法
需要改善竞争性肿瘤消退和预防复发。我们的目标是:i)确定
卵巢癌基因亚型将受益于一种新的更有效的基因靶向治疗,
来自我们临床试验的肿瘤培养物、患者来源的异种移植物模型和人肿瘤样品,ii)鉴定
获得性抗性的机制与遗传验证。
我们已经确定了一种新的和高活性的基因毒性治疗,通过共抑制聚ADP核糖聚合酶
(PARP)和ATR检查点激酶。PARP抑制与ATR抑制的组合(PARPi-ATRi)协同作用
特异性靶向并杀死携带常见HGSOC相关改变的HGSOC,例如同源
重组(HR)缺陷和细胞周期蛋白E过表达。我们的初步研究表明,PARPi-ATRi在
组合在杀死具有这些改变的HGSOC细胞方面特别有效,并导致HR-1的消退。
缺乏和细胞周期蛋白E过表达的HGSOC患者来源的异种移植物(PDX)。这些结果刺激了
PARPi-ATRi联合治疗复发性HGSOC(HGSOC患者人群)的临床试验将由
该提案的PI。这将是第一项评估PAPRi-ATRi联合治疗卵巢癌的试验。
在这里,我们建议验证体外研究结果,并扩大使用我们的PDX模型,一个可靠的HGSOC
替代物,以测试这种新型PARPi-ATRi组合在杀死HGSOC中的有效性,
过度表达细胞周期蛋白E或获得PARPi抗性,这些共同导致HGSOC的大多数死亡。我们
PARPi-ATRi治疗复发性HGSOC的临床试验将与扩展的
临床前小鼠研究。这将使我们能够将预测性生物标志物(HR缺乏和细胞周期蛋白E)
过表达)的应答和潜在的抗性机制(例如,BRCA回复突变)。
这种PARPi-ATRi联合治疗是有希望的;然而,这种治疗最初会导致肿瘤消退。
在化疗耐药细胞周期蛋白E过度表达的肿瘤中,但最终会产生获得性耐药。使用基因组
和蛋白质组学,我们将整合在PAPRi-ATRi耐药和敏感PDX中发现的改变,
从临床试验中收集患者样本,以制定候选库列表。与抗性相关的候选基因
将通过优先考虑在基因和蛋白质水平上发现的可药用的改变来改进。顶部
候选物将使用靶向CRISPR敲低方法在体外进行验证。定义标志物
反应和耐药性将有助于对患者人群进行分层,优化治疗策略,
基于HGSOC癌症遗传学的未来治疗目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FIONA SIMPKINS其他文献
FIONA SIMPKINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FIONA SIMPKINS', 18)}}的其他基金
Platform to develop targeted therapies for aggressive less common gynecological cancers
开发针对侵袭性不太常见妇科癌症的靶向疗法的平台
- 批准号:
10733237 - 财政年份:2023
- 资助金额:
$ 39.81万 - 项目类别:
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
“优化高级别浆液性卵巢癌的综合致死率”
- 批准号:
10222605 - 财政年份:2018
- 资助金额:
$ 39.81万 - 项目类别:
A novel more effective genotoxic therapy for ovarian cancer
一种新的更有效的卵巢癌基因毒性疗法
- 批准号:
10343698 - 财政年份:2018
- 资助金额:
$ 39.81万 - 项目类别:
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
“优化高级别浆液性卵巢癌的综合致死率”
- 批准号:
10478846 - 财政年份:2018
- 资助金额:
$ 39.81万 - 项目类别:
Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
靶向 SRC 信号通路促进卵巢癌细胞周期停滞
- 批准号:
8808036 - 财政年份:2011
- 资助金额:
$ 39.81万 - 项目类别:
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
靶向 Src 信号通路促进卵巢癌细胞周期停滞
- 批准号:
8112284 - 财政年份:2011
- 资助金额:
$ 39.81万 - 项目类别:
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
靶向 Src 信号通路促进卵巢癌细胞周期停滞
- 批准号:
8293101 - 财政年份:2011
- 资助金额:
$ 39.81万 - 项目类别:
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
靶向 Src 信号通路促进卵巢癌细胞周期停滞
- 批准号:
8472456 - 财政年份:2011
- 资助金额:
$ 39.81万 - 项目类别:
Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
靶向 SRC 信号通路促进卵巢癌细胞周期停滞
- 批准号:
9143971 - 财政年份:2011
- 资助金额:
$ 39.81万 - 项目类别:
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
“优化高级别浆液性卵巢癌的综合致死率”
- 批准号:
9975117 - 财政年份:
- 资助金额:
$ 39.81万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39.81万 - 项目类别:
Research Grant